Last updated: 2026-09-06 08:09:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Nephros Inc. (NEPH) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $4.15, with a market capitalization of $45.78M and a P/E ratio of 26.15. Over the past 52 weeks, its price has ranged from $2.66 to $6.42. This page covers its latest market performance, valuation, price trends and company information.
$45.78M | |
$4.15 | |
$11.67 | |
$0.91 | |
$4.18 | |
17.74K | |
-- | |
26.15 | |
$6.42 | |
$2.66 | |
-- | |
-- |
Nephros Inc. (NEPH) last closed at $4.18 as of 2026-09-04 23:31:00, unchanged from the previous close of $4.18.
During the latest regular trading session, NEPH traded between $0.91 and $11.67, with a volume of 17.74K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Nephros Inc. (NEPH) moved from $4.54 to $4.15, representing a decline of 8.66% ($0.39).
The stock traded between $4.06 and $4.26 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 19.26 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 39.5%
NEPH is currently trading at $4.15, placing it 39.5% of the way from its 52-week low of $2.66 to its 52-week high of $6.42. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 36 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Nephros Inc. (NEPH) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.